VSTM - Verastem, Inc.
| Previous Close | 1.9400 |
| Open | 1.9000 |
| Bid | 1.8400 x 4000 |
| Ask | 1.8800 x 2200 |
| Day's Range | 1.7900 - 1.9400 |
| 52 Week Range | 0.8300 - 3.6600 |
| Volume | 1,285,636 |
| Avg. Volume | 2,501,632 |
| Market Cap | 139.034M |
| Beta (5Y Monthly) | 2.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9510 |
| Earnings Date | Oct 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.75 |
- Simply Wall St.
Those Who Purchased Verastem (NASDAQ:VSTM) Shares Five Years Ago Have A 74% Loss To Show For It
Verastem, Inc. (NASDAQ:VSTM) shareholders will doubtless be very grateful to see the share price up 43% in the last...
- Zacks
Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
- Benzinga
The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 7) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) (announced ...
- Business Wire
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a global licensing agreement with Chugai Pharmaceutical Co., Ltd., (Chugai) whereby Verastem Oncology is obtaining worldwide development and commercialization rights to the RAF/MEK inhibitor CH5126766 (CKI27) from Chugai currently under development for the treatment of KRAS mutant solid tumors. The Company will host an investor call to discuss the opportunity and a development update today (details below).
- Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 110,963 shares of its common stock to eight new employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $1.33 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on January 2, 2020. 21,244 options granted to one new employee will vest at a rate of 25% on the one-year anniversary of their date of hire, and thereafter, at a rate of 6.25% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as employee of or other service provider to Verastem Oncology on each such vesting date. 89,719 options granted to seven new employees will vest a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5.00% of the shares subject to the options at the end of each successive three-month period, provided the employees continue to serve as employees of or other service providers to Verastem Oncology on each such vesting date.
- Insider Monkey
Do Hedge Funds Love Verastem Inc (VSTM)?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
- Zacks
Implied Volatility Surging for Verastem (VSTM) Stock Options
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
- Business Wire
Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the presentation of key abstracts highlighting COPIKTRA® (duvelisib) data at the American Society of Hematology 2019 Annual Meeting taking place December 7-10, 2019, in Orlando.
- Business Wire
Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for COPIKTRA® (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), seeking approval for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL). “We have seen the significant benefit of COPIKTRA as a treatment option for patients throughout our clinical trials and experience globally,” said Brian Stuglik, Chief Executive Officer of Verastem Oncology.
- Thomson Reuters StreetEvents
Edited Transcript of VSTM earnings conference call or presentation 29-Oct-19 8:30pm GMT
Q3 2019 Verastem Inc Earnings Call
- Business Wire
Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award
Verastem, Inc. (VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Andrei Shustov, M.D., Professor of Medicine and Hematology, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center and President and Founder of the T-Cell Leukemia and Lymphoma Foundation (TCLLF) has been selected to receive the Company’s Innovation in Care Award.
- Business Wire
Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048
For each $1,000 principal amount of existing notes being exchanged, the Company will deliver to the exchanging investor $550 principal amount of exchange notes and a cash payment of $100, together with accrued and unpaid interest on the existing notes (plus, if applicable, an adjustment in lieu of issuing fractional exchange notes). The exchange is expected to close on November 14, 2019, subject to customary closing conditions.
- Business Wire
Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting
Results from the Dose Optimization Portion of the Study to be Presented
- Benzinga
The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 29) Cabaletta Bio Inc (NASDAQ: CABA ) Edwards Lifesciences ...
- Zacks
Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress
Company Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA®; Reaffirms FY2019 Revenue Guidance
- Business Wire
Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress
Verastem, Inc. , a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that five posters highlighting clinical data for COPIKTRA™ will be presented at the Lymphoma & Myeloma 2019 International Congress taking place October 23-26, 2019, in New York City.
- Business Wire
Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will host a conference call and webcast on Tuesday, October 29, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2019. The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com. A replay of the webcast will be archived on the Company's website for 90 days following the call.
- Zacks
Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates
Key highlights of the past week include label expansion of drugs, licensing deals and more.
- Zacks
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
- Business Wire
Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Verastem, Inc. , , a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that its partner Yakult Honsha Co., Ltd.
- Simply Wall St.
How Many Verastem, Inc. (NASDAQ:VSTM) Shares Did Insiders Buy, In The Last Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- Business Wire
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
Verastem, Inc. , a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced duvelisib has received orphan drug designation from the U.S.
- Business Wire
Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Malignancies
Duvelisib’s Dual Inhibition of PI3K-Delta and PI3K-Gamma Inhibits Migration and Proliferation of Mantle Cell Lymphoma Cells More Effectively Than PI3K-Delta Alone in Preclinical Mo
